Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş.filedCriticalBi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş.
Priority to TR2003/01671ApriorityCriticalpatent/TR200301671A2/en
Publication of TR200301671A2publicationCriticalpatent/TR200301671A2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Mevcut bulus; depresyon tedavisinde kullanilan 1-[3-(dimethylamino)-propyl]-1- (4-fluorophenyl)-1, 3-dizohydro-5-izobenzofurancarbonitrile formülüne sahip sitalopramin formülasyonunda ortaya çikan sorunlarin giderilmesi, in vitro dissolüsyon profilinin iyilestirilmesi amaciyla gelistirilmistir.The present invention; The aim of the present invention is to improve the in vitro dissolution profile of the citalopramine formulation of the formula 1- [3- (dimethylamino) -propyl] -1- (4-fluorophenyl) -1,3-disohydro-5-isobenzofurancarbonitrile used in the treatment of depression.
TR2003/01671A2003-10-032003-10-03
Sitalopram's new production formulation.
TR200301671A2
(en)
Compounds derived from substituted 3- (4- (2-oxoindole) -piperidin) -pyrrolidines and 3- (4-benzo [b] imidazole) -piperidin) -pyrrolidines preparation process; pharmaceutical composition; intermediate compounds; Useful in the treatment of pain therapy, diseases such as Alzheimer's, anxiety, depression and glaucoma.